Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Summary
Vaxart secured a contract modification that releases additional BARDA funding for its Phase 2b COVID-19 oral pill vaccine trial. The updated award reflects the trial’s reduced scope after a partial termination and now provides about $345 million in total available funding. The company plans to use roughly $29 million of the release to finish the trial and perform deeper data analysis. Vaxart expects 12-month data from the 400-participant sentinel cohort in the coming weeks and 12-month data from the main cohort in the first half of 2027.
Funding
Amount
$29.0M
Total raised
Date
June 25, 2026
Announcement date
Investors
National Institute of Allergy and Infectious Diseases
Lead investors
Company
vaxart.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected